NASDAQ : AIKI

AIkido Pharma Inc.

$3.56 USD

$0.03 (0.85%)

Volume
31.93K
Average Volume
38.13K
Market Capitalization
$19.53M
P/E Ratio
-1.16
Dividend Yield
0.00%
Price Target
Year High
$7.27
Year Low
$0.29
Day High
—
Day Low
—
Payout Ratio
-$0.35
Current Ratio
$1.80
Company Overview

NASDAQ

Anthony C. Hayes

Biotechnology

Healthcare

AIKI

4

US

USD

https://www.aikidopharma.com

13473217646

008875106

0000012239

Liquidity Metrics

0.00

1.80

1.80

1.61

-0.35

Sales & Valuation

$123.1M

0.15

3.71

-1.15

-0.75

Profitability

-$1.57

-$22.44M

-51.93%

-33.14%

-83.27%

-120.74%

P/E Metrics

-1.16

0.02

0.02

Analyst Price Target & Rating

N/A

0/5

1 Analysts

%

Financial Health Scores

2.23

3/9

$14.2M

$85.32M

$53.74M

$139.13M

Key Metrics (TTM)

-$7.95M

-0.05

-0.06

1.70

-47.34%

-365.32%

-73.54%

-38.19%

0 days

Company Executives
Name Title
Carlos Aldavero Pres of Dominari Financial
Darrell Dotson Vice President of Drug Devel. & Gen. Counsel
Anthony C. Hayes Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer & Director
Poll Results

No votes yet today — be the first to share your view!

About AIkido Pharma Inc. (NASDAQ:AIKI) Stock

AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, ... Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.

Frequently Asked Questions

What is the current AIkido Pharma Inc. (AIKI) stock price?

AIkido Pharma Inc.(NASDAQ:AIKI) stock price is $3.56 in the last trading session. During the trading session, AIKI stock reached the peak price of $7.2673 while $0.29 was the lowest point it dropped to. The percentage change in AIKI stock occurred in the recent session was 0.85% while the dollar amount for the price change in AIKI stock was $0.03.

AIKI's industry and sector of operation?

The NASDAQ listed AIKI is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of AIKI?

Carlos Aldavero | Pres of Dominari Financial
Darrell Dotson | Vice President of Drug Devel. & Gen. Counsel
Anthony C. Hayes | Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer & Director
|
|

How many employees does AIKI have?

Number of AIKI employees currently stands at 4. AIKI operates from ONE ROCKEFELLER PLAZA, 11TH FLOOR, New York City, NY 10020, US.

Link for AIKI official website?

Official Website of AIKI is: https://www.aikidopharma.com

How do I contact AIKI?

AIKI could be contacted at phone #13473217646 and can also be accessed through its website. AIKI operates from ONE ROCKEFELLER PLAZA, 11TH FLOOR, New York City, NY 10020, US.

How many shares of AIKI are traded daily?

The average number of AIKI shares traded daily for last 3 months was 38.13K.

What is the market cap of AIKI currently?

The market value of AIKI currently stands at $19.53M with its latest stock price at $3.56